ChemoCentryx Revenue and Competitors
Estimated Revenue & Valuation
- ChemoCentryx's estimated annual revenue is currently $34.3M per year.
- ChemoCentryx's estimated revenue per employee is $439,359
- ChemoCentryx's total funding is $634.3M.
- ChemoCentryx's current valuation is $2.3B. (January 2022)
Employee Data
- ChemoCentryx has 78 Employees.
- ChemoCentryx grew their employee count by -29% last year.
ChemoCentryx's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO, President and Chairman | Reveal Email/Phone |
2 | Sr. VP, Technical Operations | Reveal Email/Phone |
3 | VP, Head Biology | Reveal Email/Phone |
4 | VP, Head Chemistry | Reveal Email/Phone |
5 | SVP, Global Regulatory Affairs | Reveal Email/Phone |
6 | EVP, COO | Reveal Email/Phone |
7 | SVP, Head Commercial | Reveal Email/Phone |
8 | SVP, Human Resources | Reveal Email/Phone |
9 | SVP Finance and Principal Accounting Officer | Reveal Email/Phone |
10 | VP, Preclinical Development, DMPK & Clinical Pharmacology | Reveal Email/Phone |
ChemoCentryx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is ChemoCentryx?
ChemoCentryx, Inc. discovers, develops and commercializes novel small molecule medicines for autoimmune diseases, inflammatory disorders, cancer and infectious disease. Traficet-EN(TM), the company's orally active drug for inflammatory bowel disease, will enter clinical trials in 2003. Other products include an orally active development candidate for rheumatoid arthritis and multiple sclerosis, and emerging drug candidates for cancer and cardiopulmonary inflammation. Another drug, T487, resulted from a ChemoCentryx discovery program and is expected to enter Phase II clinical trials for psoriasis in 2003 with partner Tularik Inc. Leveraging its leadership in chemokine-based drug discovery, ChemoCentryx focuses on new classes of orally active small molecules to selectively inhibit activity of the chemokine system, the "master regulator" of immune response. Based in San Carlos, California, ChemoCentryx is privately held.
keywords:Biotechnology, Healthcare
$634.3M
Total Funding
78
Number of Employees
$34.3M
Revenue (est)
-29%
Employee Growth %
$2.3B
Valuation
N/A
Accelerator
ChemoCentryx News
ChemoCentryx, Inc. (NASDAQ:CCXI) Receives Consensus Recommendation of Buy from Analysts. Posted by admin on Apr 21st, 2022.
ChemoCentryx is a relatively small biotech that is only now becoming a commercial company, but it beat out some major names, including AstraZeneca and Amgen's...
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer.
Other Companies in Mountain View
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $10.9M | 78 | -22% | $43M |
#2 | $13.4M | 79 | -6% | $16M |
#3 | $11.6M | 80 | 10% | N/A |
#4 | $7.5M | 80 | -33% | N/A |
#5 | $15M | 80 | 5% | N/A |